drugset / Trial / NCT06011798

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798

Phase 2 Completed 52 enrolled Unity Biotechnology, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerability of foselutoclax

Timeline

Start
2023-08-23
Primary completion
2025-01-21
Completion
2025-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Other
Subject foselutoclax Small molecule 10 ug Other